ТРУНЕ Алемсегед (US),КАРР Франсис Джозеф (GB),ДЖОНС Тимоти Дэвид (GB),ГРЕГСОН Джеймс П. (GB)
申请号：
RU2014120694/10
公开号：
RU2014120694A
申请日:
2012.10.26
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A treatment method for suppressing an immune response, comprising administering to a subject in need of treatment a naked blocking antibody that selectively binds to iNKT cells in an amount effective to suppress the function of iNKT cells in a subject in which the blocking antibody is a depleting antibody, and the amount is effective for depletion of iNKT cells. 2. The method of claim 1, wherein the subject's immune response to the antigen is suppressed. The method of claim 2, wherein the antigen is an allergen. The method of claim 1, wherein the subject is characterized by the presence of bronchial asthma, and in which the treatment suppresses one or more symptoms of bronchial asthma in the subject. The method of claim 4, wherein the bronchial asthma is allergic bronchial asthma. The method of claim 1, wherein the subject is characterized by the presence of COPD, and in which treatment suppresses one or more symptoms of COPD in the subject. The method of claim 1, wherein the subject is characterized by a disorder such as airway hyperreactivity, and the treatment suppresses one or more symptoms of the disorder in the subject. The method of claim 1, wherein the subject is a human. The method of claim 5, wherein the subject is a human. The method of claim 9, wherein the antibody is a fully human antibody. The method of claim 10, wherein the antibody comprises three regions of a light chain CDR and three regions of a heavy chain CDR, and wherein each of three regions of a light chain CDR and three regions of a heavy chain CDR is a complex of human sequences. The method of claim 10, wherein the antibody binds to iNKT cells with 1C 50, which co1. Способ лечения для подавления иммунного ответа, предусматривающий введение нуждающемуся в лечении субъекту голого блокирующего антитела, которое связывается селективно с iNKT клетками в количестве, эффективном для подавления функции iNKT клеток у субъекта, в котором блокирующее антитело представляет собой истощающее антитело,
